Daclizumab - Biologic Drug Details

Summary for daclizumab

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Recent Clinical Trials:	See clinical trials for daclizumab

Recent Clinical Trials for daclizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Alberta	Phase 1/Phase 2
Alberta Innovates Health Solutions	Phase 1/Phase 2
Northwestern University	Phase 1

See all daclizumab clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for daclizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for daclizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2013-06-25	DrugPatentWatch analysis and company disclosures
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2016-12-07	DrugPatentWatch analysis and company disclosures
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2018-04-03	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for daclizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749		2036-12-20	Patent claims search
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749		2038-08-23	Patent claims search
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749		2037-05-24	Patent claims search

International Patents for daclizumab

Country	Patent Number	Estimated Expiration
Germany	60128084
Brazil	112013001107
Japan	2022095926

Supplementary Protection Certificates for daclizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2016/053	Ireland		PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160701
132016000123360	Italy		PRODUCT NAME: DACLIZUMAB(ZINBRYTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1107, 20160705
93314	Luxembourg		NAME: DACLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/16/1107 20160705

Market Dynamics and Financial Trajectory for Daclizumab

Last updated: April 26, 2026

Daclizumab’s commercial trajectory is defined by a sharp revenue peak followed by a steep, regulation-driven collapse in the US and Europe after safety signals and product withdrawals. The biologic generated meaningful peak sales before regulatory actions ended its ability to be prescribed in the US, then left a shrinking, uneven presence internationally tied to country-level decisions and residual supply.

What was daclizumab and how did it reach the market?

Daclizumab is a monoclonal antibody that targets CD25 (IL-2 receptor alpha), used historically in multiple sclerosis under the brand Zinbryta (daclizumab beta, Biogen). It reached peak commercial adoption during periods when its efficacy supported reimbursement and specialist prescribing.

Product lifecycle anchors

• US brand: Zinbryta (daclizumab beta)
• Core indication: relapsing multiple sclerosis (market penetration primarily among MS neurology specialists)

How did the commercial market evolve over the product lifecycle?

Daclizumab’s market dynamics split into three phases: growth, peak, then contraction driven by safety and regulatory actions.

Growth and penetration (pre-safety rupture)

• Uptake depended on neurologist adoption, payer coverage for a specialist MS line, and switching from alternatives.
• As an injectable biologic, it relied on established specialty pharmacy distribution and payer authorization for MS subpopulations.

Safety signal and regulatory response (inflection point)

• Safety concerns tied to immune-mediated adverse events led regulators to move from routine labeling actions to prescriber-facing restrictions and ultimately withdrawal.
• The US FDA required withdrawal actions, including removal from the market, which stopped new patient starts and materially reduced demand.

Key regulatory impact

• FDA action: Zinbryta was withdrawn from the US market in 2018 following safety findings, eliminating new US commercial demand and collapsing expected long-run sales. (US FDA) [1]

Post-withdrawal market shrinkage (residual supply and international divergence)

• After US withdrawal, market presence became a function of:
  • remaining country authorizations,
  • residual supply,
  • competition from next-generation MS therapies (oral and injectable platform shifts),
  • payer and prescriber willingness to use an off-restriction product.
• Countries that maintained authorizations longer still saw constrained uptake due to risk management requirements and shrinking clinician confidence.

What happened to sales and financial trajectory?

Daclizumab’s financial trajectory tracks directly to the regulatory timeline: a high-sales period before 2018, then a rapid decline as the product was withdrawn and patient access ended.

Revenue trajectory (high level)

• Pre-2018: revenue rose meaningfully with adoption and reimbursement in a concentrated segment (MS specialists).
• 2018 onward: revenue collapsed due to withdrawal from the market and the end of new prescriptions.

Why the drop was structurally fast

• Withdrawal eliminates new demand rather than gradually reducing it.
• The MS market is competitive and patients can transition to other disease-modifying therapies once a product is no longer available.
• Specialty biologic revenue is highly sensitive to patient starts; withdrawal halts starts and accelerates switches.

Investor and operator financial impact pattern

• A product with significant revenue contribution but no continuity plan after withdrawal forces:
  • financial write-downs and charge-offs,
  • reduced future cash flows from the segment,
  • reallocation of R&D and marketing spend toward pipeline substitutes,
  • compression in long-term growth expectations for the MS portfolio.

The US market shutdown in 2018 is the core event that converts a growth asset into a declining or discontinued revenue line. (US FDA) [1]

How did competition change daclizumab’s pricing power and share?

Competition in MS moved quickly toward therapies with stronger safety profiles, convenient administration, and differentiated efficacy narratives. Once safety risk dominated the product storyline, daclizumab’s competitive position deteriorated on multiple dimensions:

Demand-side pressure

• Payers reduced or ended coverage for a withdrawn/regulated safety-constrained product.
• Neurologists deprioritized daclizumab as alternative MS disease-modifying therapies expanded.

Supply-side pressure

• Withdrawal constrained availability and reduced the operational ability to maintain or expand accounts.

Strategic pressure

• Even in markets where continuation was allowed temporarily, the reimbursement and clinician behavior shift typically causes rapid demand erosion ahead of formal market exits.

What regulatory and safety milestones drove the financial outcome?

The financial trajectory is tightly linked to regulatory and safety actions.

US withdrawal

• FDA withdrawal of Zinbryta in 2018 stopped the US commercialization engine, ending new patient starts and driving a rapid revenue decline. (US FDA) [1]

Broader safety framing and market perception

• Safety signals in immune-mediated adverse events led to intensified scrutiny and prescriber caution.
• In biologics, this kind of risk is often decisive because insurers and clinicians act conservatively when patient harm signals appear and benefit-risk credibility erodes.

How did the product’s market dynamics compare with typical biologic trajectories?

A typical biologic lifecycle shows gradual maturity and eventual decline due to competitive entry, label narrowing, and switching behavior. Daclizumab diverged by experiencing an abrupt demand cliff due to regulator-enforced withdrawal.

Key differences versus a “normal” decline curve

• Timing: The decline was not primarily incremental; it was triggered by withdrawal.
• Mechanism: The market exited due to safety and regulatory action rather than competitive displacement alone.
• Demand shape: New starts went to zero in the affected jurisdiction, collapsing forward revenue more quickly than competitor-driven erosion would.

What do the financial dynamics imply for R&D and investment?

Daclizumab illustrates several business-critical dynamics for biologics:

1. Safety risk can dominate market fundamentals
   When safety signals cross regulatory thresholds, sales can fall faster than competitive and pricing levers can respond.

2. Specialty drug revenues are path-dependent
   In MS, patient starts and switching decisions are decisive. Withdrawal removes a crucial part of the revenue formula.

3. Portfolio contingency matters
   Loss of a meaningful revenue asset typically forces accelerated pipeline substitution and portfolio reprioritization.

Key Takeaways

• Daclizumab’s commercial peak was followed by a sharp revenue collapse tied to safety actions and US market withdrawal in 2018. (US FDA) [1]
• The decline was structurally fast because withdrawal ends new patient starts rather than gradually reducing share.
• Post-withdrawal market presence was constrained by country-by-country authorizations, but overall demand eroded due to clinician and payer behavior and competitive MS therapy expansion.
• The case is a practical reminder that in specialty biologics, risk management and regulatory thresholds can override normal competitive pricing and share dynamics.

FAQs

1) Why did daclizumab’s revenue fall so quickly after 2018?

Because the product was withdrawn from the US market, stopping new prescriptions and accelerating patient switching to alternative MS therapies. (US FDA) [1]

2) Did daclizumab face competition primarily from other MS drugs?

Yes, but the dominant driver of demand destruction was safety-linked regulatory action. Competition still matters, yet withdrawal structurally removes the product’s ability to compete.

3) What is the key market unit for MS biologics in financial terms?

New patient starts and persistence. Withdrawal kills starts and compresses forward revenue.

4) What does the daclizumab case suggest for biologics R&D risk management?

That immune-mediated safety signals can translate into abrupt regulatory outcomes that outperform incremental commercial risks in magnitude.

5) Is the daclizumab story specific to the US?

The US withdrawal in 2018 is the clearest inflection point, but international market outcomes depend on local regulatory decisions and the degree of label restrictions and access limitations. (US FDA) [1]

---

References

[1] U.S. Food and Drug Administration. (2018). FDA Drug Safety Communication: FDA requests manufacturer to withdraw daclizumab (Zinbryta) from the market. https://www.fda.gov/